Available for Preorder: The 2023-24 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors

On October 10, 2023, Drug Channels Institute will release 2023-24 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. This report—our fourteenth edition—remains the most comprehensive, fact-based tool for understanding and analyzing the large and growing U.S. pharmaceutical distribution industry.

9 chapters, 300+ pages, 163 exhibits, 600+ endnotes: There is nothing else available that comes close to this valuable resource.

We are providing you with the opportunity to preorder this thoroughly updated, revised, and expanded 2023-24 edition at special discounted prices. This means that you can be among the first to access our new report. Those who preorder will receive a download link before October 10.

CLICK HERE to download a free pre-publication overview

(including key industry trends, the Table of Contents, and a List of Exhibits)

You can pay online with all major credit cards (Visa, MasterCard, American Express, and Discover) or via PayPal. Click here to email us if you would like to pay by corporate purchase order or check.

Special preorder and launch pricing discounts will be valid through October 20, 2023.

2023-24 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors is the definitive, nonpartisan resource thoroughly updates our annual exploration of the distribution industry’s interactions with—and services for—other participants in our healthcare system.

Our 2023-24 edition contains the most current financial and industry data. As always, we have updated all market and industry data with the most current information available. The report also updates our annual analyses of the strategies, market positions, and executive compensation of the three largest companies: AmerisourceBergen (Cencora), Cardinal Health, and McKesson.

The notable new material in this 2023-24 edition includes new data about commercial pricing and reimbursement for provider-administered biosimilars as well as updated, expanded, and reorganized data about pharmacy services administrative organizations and group purchasing organizations for small pharmacies and physician practices. New sections analyze emerging challenges from direct distribution models that bypass wholesale distribution, the acquisitions of physician practices by corporate entities and private equity, and the Inflation Reduction Act’s likely consequences for wholesalers. Download a free report overview for more details on the new sections and content.

Thank you for your interest in our work. If you have any questions before purchasing a license to the report, please email me (afein@drugchannels.net). Enjoy!